394 Results
Sort By:
Published on October 3, 2024
An international team of researchers has developed a promising new drug that works on both major Tau protein aggregation “hotspots,” a key driver of neurodegeneration including Alzheimer’s disease. The novel peptide inhibitor, RI-AG03, has demonstrated efficacy in preventing Tau aggregation in both laboratory and fruit fly studies, while showing no…
Published on September 13, 2024
Researchers from the Medical Research Council Laboratory of Molecular Biology (MRC LMB) in Cambridge, England and the UK Dementia Research Institute (UK DRI) at the University of Cambridge have developed new potential therapies that selectively remove the aggregated tau tangles to treat Alzheimer’s disease (AD). Their work, detailed in two…
Published on August 2, 2024
A novel technique developed by researchers at the Washington University (WashU) School of Medicine has allowed them to study aged neurons in the lab without the need for a brain biopsy. The technique has identified aspects of the genome of cells in the development of late-onset Alzheimer’s disease (AD) that…
Published on July 25, 2024
A research team led by the Broad Institute of MIT and Harvard has mapped gene expression across six areas of the brain linked to Alzheimer’s disease using a single-cell transcriptomics approach. Writing in Nature, the authors explain that they were able to map 1.3 million cells from 283 post-mortem brain…
Published on July 15, 2024
Dementia is an early sign of Alzheimer’s disease, but not all patients with it will go on to develop the progressive brain disorder for which there is no cure. Early detection, however, allows for the treatment of symptoms and the building support and medical care teams. Now, a team of…
Published on June 14, 2024
The Davos Alzheimer’s Collaborative (DAC) announced that it will collaborate with health systems in Germany, the U.K., Japan, the U.S., and the Netherlands to leverage blood biomarkers and confirmatory diagnostic testing to for early identification of Alzheimer’s disease and related dementias (ADRD). The goal of the Accurate Diagnosis project is…
Published on June 6, 2024
A multinational research collaboration led by researchers at the University of Kentucky Sanders-Brown Center on Aging have used long-read RNA sequencing to identify 53 new RNA isoforms in medically relevant genes related to Alzheimer’s disease (AD) and other neurodegenerative diseases. Their study, published in Nature Biotechnology, is part of an…
Published on May 28, 2024
Icahn School of Medicine at Mount Sinai researchers report that they have identified a novel method to potentially slow or even halt progression of Alzheimer’s disease (AD) by manipulating cellular interactions of protein around myeloid plaques. The new findings, published in the journal Nature Neuroscience, focuses on the role of…
Published on April 11, 2024
Research led by Columbia University in New York has uncovered a genetic variant in the gene encoding fibronectin 1 (FN1) that protects against Alzheimer’s disease in carriers of the high risk APOE4 allele. It appears to do this by preventing excessive build-up of fibronectin in the blood brain barrier, something…
Published on April 4, 2024
Research led by Washington University in St. Louis carried out in animals shows that restoring the activity of microglial cells in the brain could be a new treatment strategy for Alzheimer’s disease. Approximately 5.8 million people in the United States have Alzheimer’s disease or related dementias. Treatments for the condition…
Published on March 21, 2024
New research published today by investigators from the Boston University School of Public Health (BUSPH) and the UTHealth Houston School of Public Health has identified 17 significant genetic variants in five genomic regions that are associated with Alzheimer’s disease (AD). The study, published in the journal Alzheimer’s & Dementia: The…
Published on March 7, 2024
Researchers from the University of Illinois Urbana-Champaign studying mouse models of Alzheimer’s disease (AD) have found the earliest biomarker of the disease to date. The biomarker, a neural-specific protein in the brain, exhibits increased activity that leads to seizures associated with the earliest stages of neurodegeneration. Reporting Wednesday in EMBO…
Published on March 1, 2024
Virtual reality headsets can reveal navigational issues in people at increased risk of Alzheimer’s disease before any declines in memory appear, research shows. The headsets flagged spatial navigation problems even when there were no concerns in cognitive tests, according to the findings in Alzheimer’s & Dementia: The Journal of the…
Published on December 20, 2023
Researchers from the Perelman School of Medicine at the University of Pennsylvania report that a protein “chaperone” molecule reversed Alzheimer’s disease (AD) signs and improved memory in a mouse model. Reporting in the journal Aging Biology, the investigators examined the effect a fatty-acid molecule called 4-phenylbutyrate (PBA) which has been…
Published on December 19, 2023
Digital biomarker company Altoida which is focused on using augmented reality and machine learning to identify neurological conditions, said that new research from the RADAR-AD consortium shows the promise of using augmented reality (AR)-based cognitive assessment for early identification and assessment of people with Alzheimer’s disease (AD). The findings, published…